天津行通律师事务所 关于丹娜（天津）生物科技股份有限公司 2025 年第五次临时股东会的 法律意见书 二〇二五年十二月 关于丹娜（天津）生物科技股份有限公司 2025 年第五次临时股东会的 法律意见书 致：丹娜（天津）生物科技股份有限公司（贵公司） 天津行通律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出 席并见证贵公司2025年第五次临时股东会（以下简称"本次会议"）。 本所律师并根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）等相关法律、行政法规、 规章、规范性文件及《丹娜（天津）生物科技股份有限公司章程》（以下简称"《公 司章程》"）的规定，就本次会议的召集与召开程序、召集人资格、出席会议人 员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 1．本所律师仅就本次会议的召集与召开程序、召集人和出席现场会议人员 资格、会议表决程序及表决结果的合法性发表意见，不对本次会议所审议的议案 内容及该等议案所表述的事实或数据的真实性、准确性和完整性发表意见； 2．本所律师无法对网络投票过程进行见 ...

Core Insights - The chairman of Dana Biotech, Zhou Zeqi, emphasizes the importance of long-term investment in core technology for sustainable development in the biopharmaceutical industry [2][3] - Dana Biotech, founded in 2014, has become a leader in early diagnosis of fungal diseases in China and is set to be the first IVD company listed on the Beijing Stock Exchange [2][3] - The company has developed a "5G+ Joint Detection Scheme" to enhance the precision of diagnosing various pathogenic infections [2][5] Company Development - Zhou Zeqi returned to China in 2008 to contribute to the biopharmaceutical sector and identified a significant gap in the diagnosis of pathogenic microorganisms, particularly fungal diseases [3] - The company’s first core product, derived from the horseshoe crab's blood, allows for rapid differentiation between fungal and bacterial infections, significantly improving diagnostic speed and accuracy [4][6] - The market for invasive fungal disease diagnostic reagents in China is projected to grow from 240 million yuan in 2018 to 3.03 billion yuan by 2030, with a compound annual growth rate of 23.5% [4] Innovation and R&D - Dana Biotech has obtained 91 domestic and international patents, including 48 invention patents, and has developed a diverse product matrix including antigen-antibody tests and molecular diagnostics [6][7] - The company invests over 30 million yuan annually in R&D, accounting for more than 10% of total revenue, supporting the development of six core technology platforms [6][7] - The company has developed over 70 new products through a clinical validation process that emphasizes evidence-based medicine [7] Future Prospects - The funds raised from the upcoming IPO will be used for the construction of a new headquarters and further R&D, focusing on invasive fungal infections and AI applications in diagnostics [8][9] - AI technology is expected to enhance diagnostic efficiency and accuracy, providing multidimensional diagnostic results to assist physicians [8][9] - The company aims to establish itself as a leader in the fungal diagnostics industry, aspiring to set international standards [9]

Core Insights - A total of 19 companies have announced their performance forecasts for the year 2025, with 13 expecting profit increases, 2 forecasting profit declines, and 1 predicting a loss [1] Performance Forecast Summary - **Profit Increase**: - Companies such as Bai'ao (688796) expect a profit increase of 303.57%, with a closing price of 50.25 and a year-to-date decline of 23.63% [1] - Lixun Precision (002475) anticipates a profit increase of 26.09%, with a closing price of 58.66 and a year-to-date increase of 44.73% [1] - Other notable companies with profit increases include Hongyuan (920018) at 21.42%, Aomei (920080) at 16.44%, and China Uranium (001280) at 11.42% [1] - **Profit Decline**: - Zhongcheng (920003) forecasts a profit decline of 4.14%, with a closing price of 34.15 and a year-to-date decline of 11.39% [1] - Jinhua (920015) expects a profit decline of 5.47%, with a closing price of 51.11 and a year-to-date increase of 20.86% [1] - **Loss Forecast**: - C Muxi (688802) is predicting a loss but expects to reduce losses by 54.22%, with a closing price of 829.90 [1]

公司拟投资产品的期限最长不超过 12 个月，在上述期限内，资金可循环 滚动使用。使用期限自公司董事会审议通过之日起 12 个月内有效，如单笔产 品存续期超过前述有效期，则使用期限的有效期自动顺延至该笔交易期满之 日。 授权公司董事长、总经理行使相关投资决策权并签署相关文件，财务负责 人负责具体组织实施及办理相关事宜。 证券代码：920009 证券简称：丹娜生物 公告编号：2025-138 丹娜（天津）生物科技股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 授权委托理财情况 （一）审议情况 2025 年 12 月 3 日，公司第二届董事会第二十七次会议审议通过了《关于 使用闲置募集资金进行现金管理的议案》，同意公司使用不超过人民币 11,000 万元的闲置募集资金进行现金管理。使用闲置募集资金进行现金管理的品种应 满足安全性高、流动性好、可以保障投资本金安全等要求，主要为结构性存款、 大额存单、通知存款等本金保障型产品，且购买的产品不作抵押， ...

Investment Rating - The report suggests a focus on "innovation-driven" and "steady growth" strategies within the pharmaceutical sector, indicating a positive investment outlook for the industry [3][4]. Core Insights - The North Exchange's pharmaceutical and biotechnology sector comprises 21 companies, all classified as specialized and innovative, with a significant proportion being national and provincial champions [2][16]. - The report emphasizes the potential of innovative drugs, high-end medical devices, and robust generics as key investment areas, highlighting the importance of unique products and market share advantages [3][4]. - The medical device sector has shown the highest market value growth in 2025, with an increase of 130.47%, while traditional Chinese medicine has faced performance challenges [28][32]. Summary by Sections Industry Overview - The North Exchange's pharmaceutical sector includes five sub-sectors: traditional Chinese medicine, medical devices, medical aesthetics, biological products, and chemical pharmaceuticals [12][24]. - The average market capitalization of the 21 companies in this sector reached 3.643 billion yuan as of December 1, 2025, reflecting a year-to-date increase of 41.97% [21][23]. Sub-sector Analysis - The medical device industry led the market value growth in 2025, with a total market value increase from 6.818 billion yuan at the end of 2024 to 15.713 billion yuan by December 1, 2025 [28]. - The chemical pharmaceutical sector also performed well, with notable companies like Deyuan Pharmaceutical showing a revenue increase of 22% year-on-year in the first three quarters of 2025 [4][34]. Company Case Studies - **Innovative Drugs**: Norsland's gene therapy drug NL003 is nearing approval, targeting a significant patient population with a new treatment method [4][9]. - **Medical Devices**: Weizhu Zhiyuan focuses on smart orthopedic surgical navigation systems, emphasizing the importance of unique technology and market positioning [4][11]. - **Generics**: Deyuan Pharmaceutical is transitioning from generics to innovative drugs, with a solid historical performance and a focus on diabetes and hypertension treatments [4][34]. Performance Metrics - The report notes that the average PE TTM for the pharmaceutical sector was 32X as of December 1, 2025, with the medical device sector showing a higher valuation at 78X [15][55]. - Companies like Jinbo Biological and Norsland have seen significant stock price increases, with Jinbo's stock rising by 170.68% and Norsland by 113.10% in 2025 [41][42].

Core Viewpoint - A total of 16 companies have announced their performance forecasts for the year 2025, with 12 companies expecting profit increases and 2 companies anticipating profit declines [1] Performance Forecast Summary - **Profit Increase Companies**: - N Baiao (688796): Expected profit increase of 303.57% [1] - C Moore (688795): Expected loss reduction of 41.36% [1] - Luxshare Precision (002475): Expected profit increase of 26.09% [1] - Hongyuan (920018): Expected profit increase of 21.42% [1] - Aomei (920080): Expected profit increase of 16.44% [1] - Nant (920124): Expected profit increase of 13.02% [1] - China Uranium Industry (001280): Expected profit increase of 11.42% [1] - Taikai Ying (920020): Expected profit increase of 10.44% [1] - Danna Biotech (920009): Expected profit increase of 8.92% [1] - Xintong Electronics (001388): Expected profit increase of 5.40% [1] - Jingchuang Electric (920035): Expected profit increase of 5.00% [1] - New Henghui (301678): Expected profit increase of 4.66% [1] - Nansoft Digital (301638): Expected profit increase of 2.76% [1] - **Profit Steady and Decline Companies**: - Hai'an Group (001233): Expected steady profit with a change of 0.14% [1] - Zhongcheng Consulting (920003): Expected profit decline of -4.14% [1] - Jinhua New Materials (920015): Expected profit decline of -5.47% [1]

证券日报网讯 12月4日晚间，丹娜生物发布公告称，公司拟使用额度不超过人民币11，000万元的闲置 募集资金进行现金管理，投资品种主要为结构性存款、大额存单、通知存款等本金保障型产品，期限最 长不超过12个月，资金可循环滚动使用，使用期限自公司董事会审议通过之日起12个月内有效。 （文章来源：证券日报） ...

证券日报网讯 12月4日晚间，丹娜生物发布公告称，公司于2025年12月3日召开第二届董事会第二十七 次会议，审议通过了《关于使用募集资金置换预先已支付发行费用的自筹资金的议案》，同意使用募集 资金置换预先已支付发行费用的自筹资金人民币13，295，094.34元（不含增值税）。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 12月4日晚间，丹娜生物发布公告称，公司于2025年12月3日召开第二届董事会第二十七 次会议，审议通过了《关于调整募集资金投资项目拟投入募集资金金额的议案》，拟将"新产品研发项 目"募集资金投入由3，680.00万元调减至1，456.92万元，总部基地建设项目保持10，000.00万元不变， 合计拟投入募集资金由13，680.00万元调整为11，456.92万元。 ...

证券日报网讯 12月4日晚间，丹娜生物发布公告称，公司拟将注册资本由4，739万元变更为5，539万 元，公司类型由"股份有限公司（外商投资、未上市）"变更为"股份有限公司（外商投资、上市）"，并 相应修订《公司章程》部分条款，上述事项尚需提交股东会审议并办理工商变更登记。 （文章来源：证券日报） ...